Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,884
datasets available to search
ShareScore release 0.9.0
Dataset results
2,884 results for “cancer resistance”
Oregovomab and PLD in PARP Inhibitor Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Not Candidate for Platinum Retreatment
ClinicalTrials.gov study NCT05407584. IPD Sharing: NO. Countries: 1. Publications: 1.
Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial
ClinicalTrials.gov study NCT06288113. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Bioavailability Study of ODM-201 in Subjects With Metastatic Chemotherapy-naive Castration-resistant Prostate Cancer
ClinicalTrials.gov study NCT01784757. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer
ClinicalTrials.gov study NCT00248235. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Does Prehabilitation Improve Exercise Performance and Insulin Resistance After Surgery for Oesophago-gastric Cancer?
ClinicalTrials.gov study NCT02950324. IPD Sharing: NO. Countries: 1. Publications: 2.
Data from: Epigenomic study identifies a novel mesenchyme homeobox2-GLI1 transcription axis involved in cancer drug resistance, overall survival and therapy prognosis in lung cancer patients
Open the record for dataset details and reuse information.
Data from: Investigation of discriminant metabolites in tamoxifen-resistant and choline kinase-alpha-downregulated breast cancer cells using 1H-nuclear magnetic resonance spectroscopy
Metabolites linked to changes in choline kinase-α (CK-α) expression and drug resistance, which contribute to survival and autophagy mechanisms, are attractive targets for breast cancer therapies. We previously reported that autophagy played a causative role in driving tamoxifen (TAM) resistance of breast cancer cells (BCCs) and was also promoted by CK-α knockdown, resulting in the survival of TAM-resistant BCCs. There is no comparative study yet about the metabolites resulting from BCCs with TAM-resistance and CK-α knockdown. Therefore, the aim of this study was to explore the discriminant metabolic biomarkers responsible for TAM resistance as well as CK-α expression, which might be linked with autophagy through a protective role. A total of 33 intracellular metabolites, including a range of amino acids, energy metabolism-related molecules and others from cell extracts of the parental cells (MCF-7), TAM-resistant cells (MCF-7/TAM) and CK-α knockdown cells (MCF-7/shCK-α, MCF-7/TAM/shCK-α) were analyzed by proton nuclear magnetic resonance spectroscopy (1H-NMRS). Principal component analysis (PCA) and partial least square discriminant analysis (PLS-DA) revealed the existence of differences in the intracellular metabolites to separate the 4 groups: MCF-7 cells, MCF-7/TAM cells, MCF-7-shCK-α cells, and MCF-7/TAM/shCK-α cells. The metabolites with VIP>1 contributed most to the differentiation of the cell groups, and they included fumarate, UA (unknown A), lactate, myo-inositol, glycine, phosphocholine, UE (unknown E), glutamine, formate, and AXP (AMP/ADP/ATP). Our results suggest that these altered metabolites would be promising metabolic biomarkers for a targeted therapeutic strategy in BCCs that exhibit TAM-resistance and aberrant CK-α expression, which triggers a survival and drug resistance mechanism.
Figure 4 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 4 The anti-proliferative assay (MTT) was used to examine the EMT-6/P and EMT-6/CPR cell lines' sensitivity to cisplatin at varying doses.
Figure 16 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 16 Effect of TQ (25 mg/kg), silymarin (50 mg/kg), their combinations, cisplatin (0.7 mg/kg), and control group on serum ALT level measured by (IU/L).
Figure 10 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 10 Folds increase in caspase-3 activity and apoptosis induction in concentrations of TQ (10 µM), silymarin (10 µM), and their combination in EMT-6/CPR cell line.
Figure 15 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 15 Changes of tumor sizes in EMT-6/CPR after dissection at day 10 in all groups compared to each other, n = 7.
Figure 14 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 14 A plot of change in average tumor size (mm³) vs. time in (days) of treatment in EMT-6/CPR cell line.
Figure 21 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 21 Showed that there is no significant difference in serum creatinine between the healthy group and other treatment groups except cisplatin group. This graph was obtained by GraphPad Prism.
Figure 9 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 9 Demonstrates concentration of Caspase-3 in ng/ml in each treatment group along with the control group.
Figure 7 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 7 Anti-proliferation activity of several concentrations of TQ with 106.63 µM silymarin against EMT-6/CPR cell lines.
Figure 13 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 13 Shows that the percentage of change in tumor volume in EMT-6/CPR cell line was significant (P-value < 0.05) in all treatment groups except the silymarin group. This graph was obtained using GraphPad prism.
Figure 18 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 18 Effect of TQ (25 mg/kg), silymarin (50 mg/kg), their combinations, cisplatin (0.7 mg/kg), and control group on serum AST level measured by (IU/L).
Figure 12 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 12 A plot of change in average tumor size (mm³) vs. time in (days) of treatment in EMT-6/P cell line.
Figure 6 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 6 Anti-proliferation activity of various concentrations of silymarin with 29.58 µM TQ against EMT-6/P cell lines.
Figure 5 from: Hamed RA, Talib WH (2024) Targeting cisplatin resistance in breast cancer using a combination of Thymoquinone and Silymarin: an in vitro and in vivo study. Pharmacia 71: 1-19. https://doi.org/10.3897/pharmacia.71.e117997
Figure 5 Anti-proliferation activity of various concentrations of TQ with 142.40 µM silymarin against EMT-6/P cell lines.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.